Question 1

What is Ivonescimab?

Accepted Answer

Ivonescimab is a Other.

Question 2

How often does Ivonescimab appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 33 articles.

Question 3

When was Ivonescimab first tracked by Ergen?

Accepted Answer

First tracked on May 25, 2026.

Question 4

When was Ivonescimab last mentioned in news?

Accepted Answer

Last active on Jun 08, 2026.

Question 5

What is Ivonescimab's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Ivonescimab in global news coverage?

Accepted Answer

Attention score of 7, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving Ivonescimab?

Accepted Answer

ASCO 2026 Oncology Research Presentations (May 25, 2026, 33 articles).

Question 8

How did the "ASCO 2026 Oncology Research Presentations" event impact Ivonescimab?

Accepted Answer

Ivonescimab is a core first-in-class bispecific antibody developed by Akeso, with Phase III overall survival results from the HARMONi-6 study being a pivotal highlight at ASCO 2026. Its positive data in various cancers could lead to significant market impact.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.